Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Jun 9, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new way to improve the detection of bladder tumors using artificial intelligence (AI) during bladder examinations, known as cystoscopy. The goal is to make diagnosing bladder cancer more accurate, helping doctors identify tumors more reliably and reducing mistakes. By combining traditional methods with AI technology, researchers hope to provide clearer information about the tumors, including their size and risk of returning or worsening. This could lead to better treatment plans for patients with bladder cancer.
To join the trial, participants should be between the ages of 65 and 74 and have either a single bladder tumor (3 cm or smaller) or multiple tumors (up to 5, each 3 cm or smaller). However, people with more advanced cancer or those who have recently received certain treatments may not be eligible. If you participate, you can expect to undergo a cystoscopy procedure where the AI will assist in analyzing the images to help doctors make more informed decisions about your care. This study is currently welcoming new participants and aims to create a more standardized approach to managing bladder cancer for everyone involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • unifocal primary or recurrent suspected bladder cancer with tumor size less or equal than 3 cm
- • multifocal primary or recurrent suspected bladder cancer less or equal than 5 lesions and with tumor size less or equal than 3 cm.
- Exclusion Criteria:
- • Evidence of more than 5 tumors or more than 3 cm
- • computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)
- • computed tomography/magnetic resonance evidence of distant metastases (lymphatic or organic)
- • Exclusion criteria will include gross hematuria and bacillus Calmette-Guerin (BCG) treatment or chemotherapy within 3 months of inclusion
- • An exception will be made if patients had received only a single course of chemotherapy immediately following TUR
- • Patients objecting to the use of their data in the context of research.
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials